These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24080488)

  • 1. Chimeric antigen receptors (CARs) from bench-to-bedside.
    Savoldo B; Dotti G
    Immunol Lett; 2013; 155(1-2):40-2. PubMed ID: 24080488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise and potential pitfalls of chimeric antigen receptors.
    Sadelain M; Brentjens R; Rivière I
    Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor-redirected T cells return to the bench.
    Geldres C; Savoldo B; Dotti G
    Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting domains for chimeric antigen receptor T cells.
    Bezverbnaya K; Mathews A; Sidhu J; Helsen CW; Bramson JL
    Immunotherapy; 2017 Jan; 9(1):33-46. PubMed ID: 28000526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy.
    Temme A; Schmitz M
    Immunotherapy; 2016 Sep; 8(9):983-6. PubMed ID: 27485071
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
    Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptors for Cancer Immunotherapy.
    Geldres C; Savoldo B; Dotti G
    Methods Mol Biol; 2016; 1393():75-86. PubMed ID: 27033217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The basic principles of chimeric antigen receptor design.
    Sadelain M; Brentjens R; Rivière I
    Cancer Discov; 2013 Apr; 3(4):388-98. PubMed ID: 23550147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
    Harris DT; Kranz DM
    Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
    Zhang M; Zhang DB; Shi H
    Immunotherapy; 2017 Sep; 9(10):851-861. PubMed ID: 28877629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
    Hombach A; Pohl C; Reinhold U; Abken H
    Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies.
    Chen D; Yang J
    Transl Res; 2017 Sep; 187():11-21. PubMed ID: 28641074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
    Hammill JA; Afsahi A; Bramson JL; Helsen CW
    Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.